Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Lobe Sciences ( (TSE:LOBE) ) is now available.
Lobe Sciences Ltd. has announced the appointment of Dr. Herman Williams as the CEO of its subsidiary, Altemia, Inc., which focuses on addressing dietary needs for Sickle Cell Disease patients. Dr. Williams, a seasoned healthcare executive, will lead the 2025 launch of Altemia®, a medical food product, under physician supervision, potentially enhancing the company’s market positioning in the biopharmaceutical industry.
More about Lobe Sciences
Lobe Sciences Ltd. is a biopharmaceutical company focused on developing innovative treatments for orphan and rare diseases. The company is advancing proprietary product candidates for neurological conditions and Sickle Cell Disease, and commercializes Altemia® MF, a medical food designed to manage deficiencies in Sickle Cell Disease.
YTD Price Performance: 30.0%
Average Trading Volume: 77,324
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $4.46M
See more data about LOBE stock on TipRanks’ Stock Analysis page.